BioLineRX Wins FDA Orphan Drug Status For Rare Leukemia Treatment

Israeli phramaceutcial company BioLineRX has won FDA approval for its BL-8040 acute myeloid leukemia treatment. The drug was given orphan drug status, which is given to treatments for conditions suffered by less than 200 thousand people in the US.

Following the approval, BioLineRX will have seven years to market the drug exclusively in the US.